ImmunityBio (IBRX) Short Interest Ratio & Short Volume $3.22 -0.12 (-3.44%) Closing price 03:59 PM EasternExtended Trading$3.25 +0.02 (+0.78%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ImmunityBio Short Interest DataImmunityBio (IBRX) has a short interest of 72.12 million shares, representing 62.35% of the float (the number of shares available for trading by the public). This marks a -2.20% decrease in short interest from the previous month. The short interest ratio (days to cover) is 8.3, indicating that it would take 8.3 days of the average trading volume of 5.96 million shares to cover all short positions.Current Short Interest72,120,000 sharesPrevious Short Interest73,740,000 sharesChange Vs. Previous Month-2.20%Dollar Volume Sold Short$192.56 millionShort Interest Ratio8.3 Days to CoverLast Record DateMay 31, 2025Outstanding Shares882,620,000 sharesShort Percent of Float62.35%Today's Trading Volume7,986,447 sharesAverage Trading Volume5,958,118 sharesToday's Volume Vs. Average134% Short Selling ImmunityBio? Sign up to receive the latest short interest report for ImmunityBio and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartIBRX Short Interest Over TimeIBRX Days to Cover Over TimeIBRX Percentage of Float Shorted Over Time ImmunityBio Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/31/202572,120,000 shares $192.56 million -2.2%62.3%8.3 $2.67 5/15/202573,740,000 shares $196.89 million +7.2%63.7%9.5 $2.67 4/30/202568,760,000 shares $172.59 million +2.4%N/A9.7 $2.51 4/15/202567,180,000 shares $186.76 million +6.3%58.1%10.6 $2.78 3/31/202563,180,000 shares $190.17 million +6.1%54.6%9.8 $3.01 3/15/202559,540,000 shares $170.88 million -2.3%51.5%10.1 $2.87 2/28/202560,930,000 shares $200.46 million +7.0%52.7%9.4 $3.29 2/15/202556,960,000 shares $206.20 million +1.9%49.2%9.5 $3.62 1/31/202555,920,000 shares $192.92 million +2.5%N/A9.5 $3.45 1/15/202554,540,000 shares $130.35 million +9.1%N/A7.3 $2.39 Get the Latest News and Ratings for IBRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for ImmunityBio and its competitors with MarketBeat's FREE daily newsletter. 12/31/202450,010,000 shares $128.03 million +12.6%N/A7.6 $2.56 12/15/202444,410,000 shares $127.46 million -10.8%N/A7.3 $2.87 11/30/202449,780,000 shares $250.89 million -4.4%31.2%9.8 $5.04 11/15/202452,050,000 shares $233.70 million -1.3%32.6%10.3 $4.49 10/31/202452,750,000 shares $274.83 million +2.3%33.1%10.8 $5.21 10/15/202451,580,000 shares $190.85 million -2.1%32.3%18.4 $3.70 9/30/202452,680,000 shares $195.97 million +3.8%33.0%19.2 $3.72 9/15/202450,740,000 shares $181.65 million -1.1%31.8%17.9 $3.58 8/31/202451,290,000 shares $202.60 million +4.3%32.2%16.3 $3.95 8/15/202449,180,000 shares $195.74 million +5.2%31.6%15.2 $3.98 7/31/202446,770,000 shares $240.87 million -3.5%30.3%13.5 $5.15 7/15/202448,480,000 shares $308.33 million -1.2%31.4%7.5 $6.36 6/30/202449,080,000 shares $310.19 million -8.2%31.8%7.2 $6.32 6/15/202453,440,000 shares $318.50 million -0.1%34.6%7.5 $5.96 5/31/202453,470,000 shares $343.28 million +0.1%34.6%7.7 $6.42 5/15/202453,430,000 shares $432.78 million -3.1%38.0%7.2 $8.10 4/30/202455,140,000 shares $440.57 million +0.6%40.1%7.8 $7.99 4/15/202454,840,000 shares $287.36 million +0.1%40.1%11.7 $5.24 3/31/202454,770,000 shares $294.11 million +2.9%41.5%13.6 $5.37 3/15/202453,250,000 shares $273.17 million +3.3%40.4%13.3 $5.13 2/29/202451,550,000 shares $243.83 million +9.4%39.4%12.2 $4.73 2/15/202447,140,000 shares $225.33 million +7.3%36.1%11.4 $4.78 1/31/202443,930,000 shares $147.60 million +4.8%33.6%10.5 $3.36 1/15/202441,930,000 shares $161.43 million +3.5%32.1%6.8 $3.85 12/31/202340,520,000 shares $203.41 million +7.1%31.0%6.8 $5.02 12/15/202337,840,000 shares $162.71 million +4.7%N/A6.5 $4.30 11/30/202336,140,000 shares $133.00 million +1.4%N/A6.6 $3.68 11/15/202335,660,000 shares $145.85 million -14.9%N/A6.7 $4.09 10/31/202341,920,000 shares $131.63 million +0.7%N/A8.7 $3.14 10/15/202341,640,000 shares $54.55 million +5.3%N/A13.7 $1.31Trump’s Exec Order #14154 could be a “Millionaire-Maker” (Ad)Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape. For the moment, you can watch this interview free of charge – just click here. 9/30/202339,540,000 shares $66.82 million +8.5%30.2%14.6 $1.69 9/15/202336,440,000 shares $65.59 million +36.4%19.8%14.1 $1.80 8/31/202326,720,000 shares $43.02 million +17.4%23.5%10.7 $1.61 8/15/202322,760,000 shares $44.61 million -4.8%20.0%8.8 $1.96 7/31/202323,900,000 shares $52.58 million -0.8%22.0%6.1 $2.20 7/15/202324,100,000 shares $67.00 million +3.5%22.2%5.3 $2.78 6/30/202323,290,000 shares $64.75 million -0.6%21.5%4.8 $2.78 6/15/202323,440,000 shares $65.40 million +4.7%21.6%4.6 $2.79 5/31/202322,390,000 shares $61.57 million -10.3%20.7%3.8 $2.75 5/15/202324,960,000 shares $80.37 million -16.7%23.0%4.2 $3.22 4/30/202329,980,000 shares $83.94 million +12.6%27.6%6 $2.80 4/15/202326,630,000 shares $51.40 million -0.4%24.6%6.7 $1.93 3/31/202326,730,000 shares $48.65 million +4.7%30.7%7.7 $1.82 3/15/202325,520,000 shares $36.49 million +11.7%29.3%8.1 $1.43 2/28/202322,850,000 shares $55.75 million -3.8%26.2%10.1 $2.44 2/15/202323,760,000 shares $83.16 million -1.1%29.0%12.3 $3.50 1/31/202324,030,000 shares $91.31 million +6.2%29.3%14 $3.80 1/15/202322,630,000 shares $108.17 million +0.9%27.6%14.1 $4.78 12/30/202222,430,000 shares $113.72 million -5.5%30.1%14.5 $5.07 12/15/202223,730,000 shares $159.23 million -0.4%31.8%15.8 $6.71 11/30/202223,830,000 shares $131.30 million -1.0%28.8%13.3 $5.51 11/15/202224,080,000 shares $145.68 million +1.5%29.1%14 $6.05 10/31/202223,730,000 shares $130.52 million +1.0%28.6%14.6 $5.50 10/15/202223,490,000 shares $116.04 million -5.0%28.4%14.6 $4.94 9/30/202224,720,000 shares $122.86 million +13.6%29.8%15.6 $4.97 9/15/202221,770,000 shares $139.98 million +7.8%26.3%13.5 $6.43 8/31/202220,190,000 shares $80.76 million +6.5%24.9%13.6 $4.00 8/15/202218,950,000 shares $89.63 million +1.5%23.4%11.1 $4.73 7/31/202218,680,000 shares $72.67 million +1.2%23.2%9.7 $3.89 7/15/202218,460,000 shares $83.07 million -0.4%22.9%9.2 $4.50 6/30/202218,530,000 shares $68.93 million -3.8%23.0%9 $3.72 6/15/202219,270,000 shares $61.86 million +4.3%23.9%9.6 $3.21 5/31/202218,470,000 shares $69.45 million +8.8%23.0%10.9 $3.76 5/15/202216,980,000 shares $59.26 million -1.5%21.1%11 $3.49 4/30/202217,230,000 shares $62.54 million +4.4%21.4%11.7 $3.63 4/15/202216,500,000 shares $83.33 million +3.6%20.5%11.2 $5.05 3/31/202215,930,000 shares $89.37 million -4.4%N/A10.7 $5.61 3/15/202216,670,000 shares $89.52 million +2.0%20.7%9.9 $5.37 2/28/202216,350,000 shares $111.83 million +12.2%20.3%9.6 $6.84 2/15/202214,570,000 shares $102.43 million +12.2%18.1%7.8 $7.03 1/31/202212,990,000 shares $75.60 million +4.6%16.2%7.6 $5.82 1/15/202212,420,000 shares $82.84 million +0.9%N/A7.7 $6.67 12/31/202112,310,000 shares $74.84 million +18.0%15.3%8.3 $6.08 12/15/202110,430,000 shares $59.45 million +9.4%13.0%8.3 $5.70 11/30/20219,530,000 shares $74.24 million +4.7%12.7%8.4 $7.79 11/15/20219,100,000 shares $64.97 million +2.6%12.1%9.4 $7.14 10/29/20218,870,000 shares $69.45 million -3.7%12.0%9.7 $7.83 10/15/20219,210,000 shares $85.65 million -5.3%12.4%10.5 $9.30 9/30/20219,730,000 shares $94.77 million +3.3%13.1%11.4 $9.74 9/15/20219,420,000 shares $90.15 million +2.2%12.7%10 $9.57Trump’s Exec Order #14154 could be a “Millionaire-Maker” (Ad)Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape. For the moment, you can watch this interview free of charge – just click here. 8/31/20219,220,000 shares $104.92 million -4.2%13.5%8.6 $11.38 8/13/20219,620,000 shares $108.23 million No Change14.2%8.9 $11.25 IBRX Short Interest - Frequently Asked Questions What is ImmunityBio's current short interest? Short interest is the volume of ImmunityBio shares that have been sold short but have not yet been closed out or covered. As of May 15th, investors have sold 73,740,000 shares of IBRX short. 63.75% of ImmunityBio's shares are currently sold short. Learn More on ImmunityBio's current short interest. What is a good short interest ratio for ImmunityBio? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. IBRX shares currently have a short interest ratio of 10.0. Learn More on ImmunityBio's short interest ratio. Which institutional investors are shorting ImmunityBio? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of ImmunityBio: Jane Street Group LLC, Caption Management LLC, Sculptor Capital LP, Affinity Asset Advisors LLC, and National Bank of Canada FI. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for ImmunityBio? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 63.75% of ImmunityBio's floating shares are currently sold short. Is ImmunityBio's short interest increasing or decreasing? ImmunityBio saw a increase in short interest in May. As of May 15th, there was short interest totaling 73,740,000 shares, an increase of 7.2% from the previous total of 68,760,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does ImmunityBio's short interest compare to its competitors? 63.75% of ImmunityBio's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to ImmunityBio: Blueprint Medicines Co. (9.26%), Roivant Sciences Ltd. (11.23%), Revolution Medicines, Inc. (12.20%), Verona Pharma plc (10.60%), BridgeBio Pharma, Inc. (15.63%), Elanco Animal Health Incorporated (5.58%), Grifols, S.A. (1.46%), TG Therapeutics, Inc. (16.20%), Nuvalent, Inc. (13.13%), Legend Biotech Co. (4.15%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($29.20 billion), Strategy Incorporated ($10.88 billion), iShares 20+ Year Treasury Bond ETF ($10.04 billion), Capital One Financial Co. ($5.51 billion), Charter Communications, Inc. ($5.00 billion), Super Micro Computer, Inc. ($4.43 billion), Apollo Global Management, Inc. ($4.02 billion), Hims & Hers Health, Inc. ($3.65 billion), VanEck Semiconductor ETF ($3.27 billion), and Coinbase Global, Inc. ($3.10 billion). View all of the most shorted stocks. What does it mean to sell short ImmunityBio stock? Short selling IBRX is an investing strategy that aims to generate trading profit from ImmunityBio as its price is falling. IBRX shares are trading down $0.10 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against ImmunityBio? A short squeeze for ImmunityBio occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of IBRX, which in turn drives the price of the stock up even further. How often is ImmunityBio's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IBRX, twice per month. The most recent reporting period available is May, 15 2025. More Short Interest Resources from MarketBeat Related Companies Blueprint Medicines Short Interest Roivant Sciences Short Interest Revolution Medicines Short Interest Verona Pharma Short Interest BridgeBio Pharma Short Interest Elanco Animal Health Short Interest Grifols Short Interest TG Therapeutics Short Interest Nuvalent Short Interest Legend Biotech Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:IBRX) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunityBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunityBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IBRX Stock Free IBRX Stock Alerts